异形选择性Akt3降解剂的设计,合成和生物评估
Ye-Bin Wu1, Qiu-Hua Zhou1, Xiao-Jun Ji1
1Innovation Department of the Research Institute, Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd., Nanjing 210046, P. R. China.
Journal of medicinal chemistry
|August 22, 2025
概括
研究人员开发了一种新型化合物,可选择性降解与癌症相关的Akt3激酶. 这种有针对性的方法旨在通过专门消除Akt3而改善癌症治疗,而不会影响相关蛋白质.
科学领域:
- 分子生物学
- 医学化学
- 癌症学
背景情况:
- PI3K-Akt-mTOR通路在细胞信号传递中至关重要,并且在癌症中经常失调.
- 这一途径中的Akt3是氨酸/氨酸激酶,在几个癌症中过度激活,呈现出治疗点.
- 为最大限度地提高治疗效益并最大限度地减少副作用,选择性向Akt异型是必要的.
研究的目的:
- 设计和合成能够选择性降解Akt3的新化合物.
- 评估连接器长度和E3连接体选择对Akt3降解的影响.
- 为潜在的癌症治疗确定一种强效和选择性的Akt3降解剂.
主要方法:
- 一系列化合物的合成,链接剂和E3配体不同.
- 对癌细胞系中的Akt3降解的化合物功效和选择性的评估.
- 蛋白质组分析以确认目标特异性并评估非目标效应.
主要成果:
- 连接器长度和E3连接体显著影响了Akt3降解的有效性.
- 化合物12在多种癌细胞系中显示出Akt3的强大和选择性降解.
- 蛋白质组分析证实了化合物12对Akt3的特异性,对其他蛋白质的影响最小.
结论:
- 化合物12是一种高度选择性的Akt3降解剂,通过化学合成和蛋白质组学研究得到验证.
- 这些发现突显了针对癌症治疗的向蛋白质降解的潜力.
- 需要进一步研究化合物12的治疗效果,因为它在体外缺乏抗增殖活性.
相关概念视频
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K


